An issue of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) debt fell 0.8% as a percentage of its face value during trading on Monday. The high-yield issue of debt has a 7.25% coupon and is set to mature on January 15, 2022. The debt is now trading at $86.00. Price changes in a company’s debt in credit markets sometimes predict parallel changes in its stock price.
ENDP has been the topic of several research reports. Goldman Sachs Group initiated coverage on Endo International in a research report on Thursday, September 28th. They issued a “sell” rating and a $7.00 target price on the stock. Royal Bank of Canada decreased their target price on Endo International from $9.00 to $8.00 and set a “sector perform” rating on the stock in a research report on Friday, November 10th. Guggenheim initiated coverage on Endo International in a research report on Tuesday. They issued a “neutral” rating and a $8.50 target price on the stock. Cantor Fitzgerald decreased their target price on Endo International from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $9.00 target price on shares of Endo International in a research report on Sunday, September 17th. Three equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $11.48.
Shares of Endo International PLC (NASDAQ ENDP) traded up $0.16 on Wednesday, hitting $7.88. The stock had a trading volume of 5,482,300 shares, compared to its average volume of 7,109,283. Endo International PLC has a one year low of $5.77 and a one year high of $17.99. The company has a market cap of $1,723.98, a PE ratio of 1.60, a price-to-earnings-growth ratio of 2.10 and a beta of 0.59. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78.
Large investors have recently made changes to their positions in the stock. Blair William & Co. IL bought a new position in Endo International during the 2nd quarter worth $126,000. Point View Wealth Management Inc. raised its position in Endo International by 16.6% during the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after purchasing an additional 1,900 shares during the last quarter. Riverhead Capital Management LLC raised its position in Endo International by 64.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after purchasing an additional 5,887 shares during the last quarter. Bank of Hawaii bought a new position in Endo International during the 2nd quarter worth $180,000. Finally, LMR Partners LLP bought a new position in Endo International during the 3rd quarter worth $148,000. 93.17% of the stock is owned by institutional investors and hedge funds.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
What are top analysts saying about Endo International? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endo International and related companies.